{"disease":{"id":"thrombocytopenic-purpura","name":"thrombocytopenic purpura"},"drugs":{"marketed":[{"drug_id":"rituxan","indication_name":"Thrombotic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituxan","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody","quality_score":45,"revenue":"3800","mechanism":""},{"drug_id":"romiplostim","indication_name":"Chronic idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nplate","generic_name":"ROMIPLOSTIM","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"Thrombopoietin Receptor Agonist [EPC]","quality_score":70,"revenue":"1524.0","mechanism":"Nplate works by binding to the thrombopoietin receptor to stimulate platelet production."},{"drug_id":"eltrombopag","indication_name":"Chronic idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Promacta","generic_name":"ELTROMBOPAG","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"Thrombopoietin Receptor Agonist","quality_score":80,"revenue":"569","mechanism":"Promacta works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow."},{"drug_id":"azathioprine","indication_name":"Refractory idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imuran","generic_name":"AZATHIOPRINE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Purine Antimetabolite [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-acetate","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-acetate","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"prednison","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"caplacizumab-yhdp","indication_name":"Thrombotic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CABLIVI","generic_name":"CAPLACIZUMAB-YHDP","company_name":"ABLYNX NV","drug_phase":"marketed","molecular_target":"von Willebrand factor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"methylprednisolone","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"hydrocortisone","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"fostamatinib","indication_name":"Chronic idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavalisse","generic_name":"FOSTAMATINIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"Receptor-type tyrosine-protein kinase FLT3","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Tavalisse works by blocking the activity of the FLT3 enzyme, which is involved in the production of platelets."},{"drug_id":"ruxience","indication_name":"Thrombotic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"Rituximab-Pvvr","company_name":"Roche","drug_phase":"marketed","molecular_target":"CD20 antigen on pre-B and mature B-lymphocytes","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC."},{"drug_id":"rituximab","indication_name":"Thrombotic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituximab","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction."},{"drug_id":"caplacizumab","indication_name":"Thrombotic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Calibvi","generic_name":"CAPLACIZUMAB","company_name":"Ablynx Nv","drug_phase":"marketed","molecular_target":"von Willebrand factor","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Calibvi works by binding to von Willebrand factor, preventing it from interacting with platelets and forming blood clots."},{"drug_id":"betamethasone","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"cortisol","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolon","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisone","indication_name":"Idiopathic thrombocytopenic purpura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"nplate","indication_name":"Chronic idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nplate","company_name":"Nantes University Hospital","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dexamethasone-phosphate","indication_name":"Idiopathic thrombocytopenic purpura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-succinate","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":27,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06727669","title":"Longitudinal Cohort of Thrombosis and Hemostasis Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT05950750","title":"Turkey Thrombotic Thrombocytopenic Purpura Disease Registry: National Multicenter Study","phase":"","overall_status":"RECRUITING","enrollment_count":960,"lead_sponsor_name":"Turkish Hematology Association","has_results":false},{"nct_id":"NCT07426107","title":"Development and Prospective Validation of an AI Model for Prognosis in ITP Patients Undergoing Coronary Revascularization","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Xiao Hui Zhang","has_results":false},{"nct_id":"NCT03219723","title":"Drug Use Surveillance of Takecab for \"Supplement to Helicobacter Pylori Eradication\"","phase":"","overall_status":"COMPLETED","enrollment_count":560,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT05571774","title":"Construction of a Database for TTP","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT04057703","title":"Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia.","phase":"","overall_status":"COMPLETED","enrollment_count":454,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT04014413","title":"Safety and Efficacy of Fecal Microbiota Transplantation","phase":"NA","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT03222843","title":"Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":424,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT00508820","title":"An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":407,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06873672","title":"Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":360,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT04985318","title":"Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP","phase":"","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"University of Cologne","has_results":false},{"nct_id":"NCT03369314","title":"Observational Study of the Use of octaplasLG®.","phase":"","overall_status":"COMPLETED","enrollment_count":263,"lead_sponsor_name":"Octapharma","has_results":false},{"nct_id":"NCT04981028","title":"The ConNeCT Study: Neurological Complications of TTP","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Liverpool University Hospitals NHS Foundation Trust","has_results":false},{"nct_id":"NCT00415532","title":"Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":234,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05876221","title":"Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura","phase":"","overall_status":"COMPLETED","enrollment_count":223,"lead_sponsor_name":"University of Cologne","has_results":false},{"nct_id":"NCT06722235","title":"A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":171,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT00907478","title":"Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":169,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05220878","title":"Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"AO GENERIUM","has_results":false},{"nct_id":"NCT05492409","title":"Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"AO GENERIUM","has_results":false},{"nct_id":"NCT04071496","title":"Diagnostic of Chronic Thrombocytopenia","phase":"","overall_status":"COMPLETED","enrollment_count":158,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT05389007","title":".German TTP-Registry (Thrombotic Thrombocytopenic Purpura)","phase":"","overall_status":"UNKNOWN","enrollment_count":156,"lead_sponsor_name":"Johannes Gutenberg University Mainz","has_results":false},{"nct_id":"NCT06948318","title":"A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT03605511","title":"TTP and aHUS in Complicated Pregnancies","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT06757257","title":"Special Drug Use-results Survey for Long-term Use (Fostamatinib)","phase":"","overall_status":"RECRUITING","enrollment_count":149,"lead_sponsor_name":"Kissei Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06376786","title":"Italian iTTP Registry","phase":"","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Fondazione Luigi Villa","has_results":false},{"nct_id":"NCT04070612","title":"National Prospective Cohort for Monitoring Children With Severe Autoimmune Cytopenia.","phase":"","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT02134171","title":"Early Predictive Factors of Cardiac and Cerebral Involvement in TMA","phase":"NA","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03524612","title":"A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02878603","title":"Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT05568147","title":"Aspirin for Prophylaxis of TTP","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT07150286","title":"Helicobacter Pylori Eradication Therapy for Immune Thrombocytopenia (ITP) Patients in Iraq","phase":"NA","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Al-Mustansiriyah University","has_results":false},{"nct_id":"NCT04890041","title":"TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT07429942","title":"A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Received Recombinant ADAMTS13 (rADAMTS13) as Part of the Early Access Program","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":94,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT01988506","title":"Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04056507","title":"Immunological Markers in Adult Patients With Immune Thrombocytopenic Purpura","phase":"","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT05585944","title":"\" Effect of Single-nucleotide Polymorphism of CD40 Gene rs1883832 C/T on the Risk of Immune Thrombocytopenic Purpura \"","phase":"NA","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Sohag University","has_results":false},{"nct_id":"NCT03864796","title":"Role of CD11a in Pathogenesis of Primary ITP and Effect of Immunosuppressive Therapy on Its Level","phase":"","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT04683003","title":"A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":77,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT02076399","title":"A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Rigel Pharmaceuticals","has_results":true},{"nct_id":"NCT01143038","title":"Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03237819","title":"Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":74,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04070599","title":"Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT01071954","title":"A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT00102323","title":"AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT00102336","title":"AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT00157079","title":"Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT04720261","title":"Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":58,"lead_sponsor_name":"University Hospital, Rouen","has_results":false},{"nct_id":"NCT07310342","title":"Physical Fitness of Children, Adolescents and Young Adults With Immune Thrombocytopenic Purpura","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":53,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT03393975","title":"A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT05468320","title":"Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Sanofi","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}